Affinivax, a clinical stage biotechnology company with its novel MAPS technology platform for vaccines and immunotherapies, today announced the completion of a $120 million Series B financing round, led by Viking Global Investors with participation from Bain Capital Life Sciences and Ziff Capital Partners.
Agastiya Biotech announces it has discovered its previously tested anti-cancer small molecule AB001 as a viable SARS-CoV-2 virus therapeutic.
Gilead Sciences and its subsidiary Kite have joined forces with oNKo-innate to discover and develop cancer immunotherapies focused on natural killer (NK) cells.
Revive Therapeutics has engaged Complete Phytochemical Solutions, which specialises in unique and complex analyses and formulation development of phytochemicals, to advance the Company’s research and development initiatives of psilocybin-based products for the pharmaceutical market.
The Kluyver Center for Genomics of Industrial Fermentation in Delft, Holland, is a consortium of several different Universities and Research Centres.
LegoChem Biosciences, based in Daejeon, South Korea, announced today that it has entered a research collaboration and license agreement with Iksuda Therapeutics (“Iksuda”) for the development of antibody-drug conjugates in oncology.
Starpharma announced that its proprietary VivaGel active, astodrimer sodium (SPL7013), has been shown in laboratory studies to have significant antiviral activity against the coronavirus that causes COVID-19 (coronavirus disease).
Moderna has secured a funding commitment of up to $483m from the US Government agency Biomedical Advanced Research and Development Authority (BARDA) to advance the development of messenger RNA (mRNA) vaccine for novel coronavirus (SARS-CoV-2).
Novartis has collaborated with TScan Therapeutics for the discovery and development of T cell receptor (TCR) therapies to treat solid tumours.
British drugmaker GlaxoSmithKline (GSK) has joined forces with French pharma company Sanofi for the development of an adjuvanted vaccine for COVID-19 disease.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.